Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA

Antigen-specific T lymphocyte responses elicited by a DNA – MVA HIV CN54gp140 immunization regime are significantly altered by the TLR4 adjuvant GLA

Bibliographic Details
Main Authors:	McKay PF, Cope AV, Swales J, Joseph S, Esteban M, Tatoud R, Carter D, Weber J, Shattock RJ
Format:	Article
Language:	English
Published:	BMC 2012-09-01
Series:	Retrovirology

Similar Items

Optimising CN54gp140 plasmid delivery by comparing intramuscular and intradermal vaccination combinations with and without electroporation
by: Mann JF, et al.
Published: (2012-09-01)

Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
by: Frank Msafiri, et al.
Published: (2020-11-01)

Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.
by: Viviana Buffa, et al.
Published: (2012-01-01)

P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140
by: Shattock RJ, et al.
Published: (2009-10-01)

P11-12. A novel vaginal ring device for the sustained delivery of recombinant C-clade HIV-1 CN54gp140
by: Shattock R, et al.
Published: (2009-10-01)

Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.
by: Agricola Joachim, et al.
Published: (2016-01-01)

Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.
by: Mauricio A Arias, et al.
Published: (2012-01-01)

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen.
by: Paul F McKay, et al.
Published: (2014-01-01)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

P11-09. Mucosal vaccination with a transferrin-gp140 conjugate via the nasal but not vaginal route elicits robust systemic and vaginal IgG and IgA responses
by: Shattock RJ, et al.
Published: (2009-10-01)

P19-54 LB. Interrogating the membrane-proximal external region (MPER) of HIV-1 gp140
by: Van Roey G, et al.
Published: (2009-10-01)

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.
by: Edna O Viegas, et al.
Published: (2018-01-01)

A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens
by: Sven Kratochvil, et al.
Published: (2017-05-01)

P11-06. Intravaginal administration of HIV-1ZM96 gp140 augments systemic and mucosal antibody responses following systemic priming with adjuvanted protein
by: Almond N, et al.
Published: (2009-10-01)

Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse model.
by: Godfrey A Dzhivhuho, et al.
Published: (2018-07-01)

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.
by: Natasha Dubois Cauwelaert, et al.
Published: (2016-01-01)

Targeting HIV-1 Env gp140 to LOX-1 Elicits Immune Responses in Rhesus Macaques.
by: Gerard Zurawski, et al.
Published: (2016-01-01)

The adjuvant AlhydroGel elicits higher antibody titres than AddaVax when combined with HIV-1 subtype C gp140 from CAP256.
by: Michiel T van Diepen, et al.
Published: (2018-01-01)

5.4 MATRIX GLA PROTEIN IN RELATION TO LEFT VENTRICULAR DIASTOLIC FUNCTION
by: Thibault Petit*, et al.
Published: (2015-11-01)

Mucosal application of gp140 encoding DNA polyplexes to different tissues results in altered immunological outcomes in mice.
by: Jamie F S Mann, et al.
Published: (2013-01-01)

GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.
by: Christopher H Clegg, et al.
Published: (2014-01-01)

Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
by: Sven Kratochvil, et al.
Published: (2017-12-01)

Inverse dose-response to gp140 YU2 foldon trimer formulated with aluminum phosphate and ISCOMATRIX® adjuvants
by: Wilson A, et al.
Published: (2012-09-01)

P19-06. The first hypervariable loop and HIV-1 neutralizing antibodies elicited by gp140 env immunogens
by: Stamatatos L, et al.
Published: (2009-10-01)

Corrigendum: Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination
by: Sven Kratochvil, et al.
Published: (2018-02-01)

P14-06. Phase 1 safety and immunogenicity randomised controlled trial of a vaginal gp140 vaccine
by: Giemza E, et al.
Published: (2009-10-01)

Rapid development of cross-clade neutralizing antibody responses after clade B gp120/gp140 protein priming and clade c gp140 protein boosting
by: Spearman P, et al.
Published: (2012-09-01)

Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginally.
by: David J Lewis, et al.
Published: (2011-01-01)

Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
by: Sunil K Khattar, et al.
Published: (2013-01-01)

Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response.
by: Behnaz Heydarchi, et al.
Published: (2016-01-01)

Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses
by: McKay PF, et al.
Published: (2012-09-01)

TLR4 and TLR7/8 Adjuvant Combinations Generate Different Vaccine Antigen-Specific Immune Outcomes in Minipigs when Administered via the ID or IN Routes.
by: Paul F McKay, et al.
Published: (2016-01-01)

A "prime-pull" vaccine strategy has a modest effect on local and systemic antibody responses to HIV gp140 in mice.
by: John S Tregoning, et al.
Published: (2013-01-01)

Characterization and Immunogenicity of HIV Envelope gp140 Zera® Tagged Antigens
by: Phindile Ximba, et al.
Published: (2020-04-01)

Enhancement of GLA content in Spirulina platensis and synthesis of GLA-enriched Triglyceride
by: Hsin-Hui Wang, et al.

Evolution of Matrix Gla and Bone Gla Protein Genes in Jawed Vertebrates
by: Nicolas Leurs, et al.
Published: (2021-03-01)

Molecular Signatures of a TLR4 Agonist-Adjuvanted HIV-1 Vaccine Candidate in Humans
by: Jenna Anderson, et al.
Published: (2018-02-01)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
by: Sunil K. Khattar, et al.
Published: (2014-01-01)

Retraction: Comparative immunogenicity of HIV-1 gp160, gp140 and gp120 expressed by live attenuated newcastle disease virus vector.
by: PLOS ONE Editors
Published: (2020-01-01)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector.
by: Sunil K. Khattar, et al.
Published: (2014-01-01)